Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP, 0.004%

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). Glenmark’s Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz.

According to IQVIATM sales data for the 12-month period ending September 2024, the Travatan Z Ophthalmic Solution USP, 0.004% market achieved annual sales of approximately $66.2 million.

Commenting on the launch, Jim Brown, Senior Vice President, Sales & Marketing said, “We are excited to announce the launch of Travoprost Ophthalmic Solution USP, 0.004%, growing our portfolio of prescription ophthalmic products. This addition highlights our commitment to meeting market needs and providing high-quality solutions for our customers.”

Glenmark’s current portfolio consists of 200 products authorized for distribution in the U.S. marketplace and 51 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.